These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2312764)

  • 41. Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.
    Levitt DG; Schoemaker RC
    BMC Clin Pharmacol; 2006 Jan; 6():1. PubMed ID: 16398929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zatebradine: pharmacokinetics of a novel heart-rate-lowering agent after intravenous infusion and oral administration to healthy subjects.
    Roth W; Bauer E; Heinzel G; Cornelissen PJ; van Tol RG; Jonkman JH; Zuiderwijk PB
    J Pharm Sci; 1993 Jan; 82(1):99-106. PubMed ID: 8429501
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of raclopride formulations. Influence of prolactin and tolerability in healthy male volunteers.
    Movin-Osswald G; Nordström AL; Hammarlund-Udenaes M; Wahlén A; Farde L
    Clin Pharmacokinet; 1992 Feb; 22(2):152-61. PubMed ID: 1551292
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril.
    Macdonald NJ; Elliott HL; Hughes DM; Reid JL
    Br J Clin Pharmacol; 1993 Sep; 36(3):201-4. PubMed ID: 9114904
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of food on the pharmacokinetics of a dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240.
    Cirillo I; Martin NE; Brennan B; Barrett JS
    J Clin Pharmacol; 2004 Dec; 44(12):1379-84. PubMed ID: 15545308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of fosinoprilat in Chinese and whites after intravenous administration.
    Hu OY; Ding PY; Huang CS; Hwang GM; Chu KM
    J Clin Pharmacol; 1997 Sep; 37(9):834-40. PubMed ID: 9549638
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioavailability and pharmacokinetics of a fixed combination of delapril/indapamide following single and multiple dosing in healthy volunteers.
    Hutt V; Pabst G; Dilger C; Poli G; Acerbi D
    Eur J Drug Metab Pharmacokinet; 1994; 19(1):59-69. PubMed ID: 7957454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pentopril-cimetidine interaction caused by a reduction in hepatic blood flow.
    Kochak GM; Rakhit A; Thompson TN; Hurley ME
    J Clin Pharmacol; 1988 Mar; 28(3):222-7. PubMed ID: 3360970
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spirapril: pharmacokinetic properties and drug interactions.
    Grass P; Gerbeau C; Kutz K
    Blood Press Suppl; 1994; 2():7-13. PubMed ID: 8061850
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
    Nussberger J; Wuerzner G; Jensen C; Brunner HR
    Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Hockings N; Ajayi AA; Reid JL
    Br J Clin Pharmacol; 1986 Apr; 21(4):341-8. PubMed ID: 3011046
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of intravenous and oral enoxacin in healthy volunteers.
    Chang T; Black A; Dunky A; Wolf R; Sedman A; Latts J; Welling PG
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():49-56. PubMed ID: 3162901
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics of RU44403, an active form of newly developed angiotensin-converting enzyme inhibitor (RU44570) in the rat.
    Hirayama M; Kurihara A; Manabe T; Hasegawa Y
    Drug Metab Dispos; 1994; 22(4):601-6. PubMed ID: 7956736
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Bioanalytic examination and pharmacokinetics of captopril. Bioequivalence studies of different captopril-containing Tensiomin preparations].
    Klebovich I; Benköné MS
    Acta Pharm Hung; 1997 Jul; 67(4):123-35. PubMed ID: 9289940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bioavailability and pharmacokinetics of oxazepam.
    Sonne J; Loft S; Døssing M; Vollmer-Larsen A; Olesen KL; Victor M; Andreasen F; Andreasen PB
    Eur J Clin Pharmacol; 1988; 35(4):385-9. PubMed ID: 3197746
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses.
    Serrano-Rodríguez JM; Gómez-Díez M; Esgueva M; Castejón-Riber C; Mena-Bravo A; Priego-Capote F; Serrano Caballero JM; Muñoz A
    Vet J; 2016 Feb; 208():38-43. PubMed ID: 26639833
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and pharmacodynamics of pentopril, a new angiotensin-converting-enzyme inhibitor in humans.
    Rakhit A; Hurley ME; Tipnis V; Coleman J; Rommel A; Brunner HR
    J Clin Pharmacol; 1986 Mar; 26(3):156-64. PubMed ID: 3007583
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and pharmacodynamics of enalapril and its active metabolite, enalaprilat, at four different doses in healthy horses.
    Gómez-Díez M; Muñoz A; Caballero JM; Riber C; Castejón F; Serrano-Rodríguez JM
    Res Vet Sci; 2014 Aug; 97(1):105-10. PubMed ID: 24972864
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Fosinopril: pharmacokinetics and pharmacodynamics in congestive heart failure.
    Kostis JB; Garland WT; Delaney C; Norton J; Liao WC
    Clin Pharmacol Ther; 1995 Dec; 58(6):660-5. PubMed ID: 8529331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics and pharmacodynamics of idrapril in rats, dogs, and humans.
    Criscuoli M; Lippi A; Mengozzi G; Sardelli G; Subissi A; Giachetti A
    Drug Metab Dispos; 1993; 21(5):835-40. PubMed ID: 7902245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.